Search bioRxiv⌕ Search

Biology subjects

Rana, M. M.

Publications and source records attributed to Rana, M. M..

3 recordsLinked to original sources

Mesaconate-Based Polyester Nanoparticles Reveal How Metabolite Isomerism Shapes Polymer Behavior, Macrophage Reprogramming, and Systemic Immunomodulation

Metabolite-based polymer nanoparticles can transform endogenous immunometabolites into intrinsically bioactive materials, yet most platforms have focused on itaconate or soluble metabolite analogs. Mesaconate is a downstream itaconate-derived immunometabolite with distinct metabolic activity, but its potential as an engineerable material building block remains largely unexplored. Here, mesaconic acid was used as a monomer to construct a degradable, cargo-free polyester nanoparticle platform. Poly(itaconate-co-decanediol) (pITA) and poly(mesaconate-co-decanediol) (pMSA) were synthesized using 1,10-decanediol and formulated into nanoparticles. Varying pMSA synthesis conditions generated distinct molecular-weight development, thermal organization, and degradation-associated behavior. Despite comparable particle size, surface charge, and morphology, pITA- and pMSA-derived nanoparticles produced activation-state-dependent macrophage immunomodulation. Under inflammatory stimulation, both nanoparticles modulated activation-associated surface molecules, whereas their transcriptomic responses diverged markedly. pITA-NPs preferentially engaged redox-, metabolic-, and cellular stress-associated programs, while pMSA-NPs exhibited a distinct lysosome-associated, inflammatory, and remodeling transcriptional profile and remained distinguishable from soluble 4-octyl itaconate. In LPS-induced endotoxemia, pMSA-NP treatment broadly modulated systemic cytokine responses, including a pronounced reduction in circulating IL-6, and improved seven-day survival relative to vehicle control. Together, these findings establish mesaconate as a synthesis-tunable polymeric immunometabolite and highlight metabolite-isomer identity and nanoparticle material state as complementary design parameters for cargo-free immunometabolic biomaterials.

bioengineering↗

TFE3 fusions drive expression of CD44 and SPP1 in Translocation Renal Cell Carcinoma

Xp11.2 translocation RCC [Xp11.2 tRCC]) is an underdiagnosed and aggressive subtype of RCC with few specific or targeted therapies. The transmembrane glycoprotein CD44 is an emerging target in many advanced malignancies, and with its ligand OPN (SPP1), is a crucial driver of cancer progression, stemness, metastasis, and immune suppression. Here we show that common TFE3-fusions [ including SFPQ-TFE3, PRCC-TFE3, ASPSCR1-TFE3, and NONO-TFE3] are associated with upregulated expression of CD44 and SPP1, as observed in multiple human and murine bulk transcriptomic studies and a murine tRCC snRNA-Seq dataset. CD44 and/or SPP1 protein expression were also upregulated in murine models of transgenic tRCC kidneys and urine specimens, patient-derived cell lines and human tRCC cases, by immunoblotting and/or IHC. Transient deletion of CD44 was associated with profound and specific suppression of tRCC cell line growth, with decreased mTOR signaling. These data suggest that CD44 and/or SPP1 may potentially drive tumorigenesis in tRCC.

cancer biology↗

Targeting Tumor Immunity: Statins as a Repurposed Strategy for Preventing Ovarian Cancer Advancement

High-grade serous ovarian carcinoma (HGSOC) remains the most lethal gynecologic malignancy, characterized by a high recurrence rate and poor long-term survival. Although daily statin use is associated with improved survival in ovarian cancer patients, the underlying mechanism of this benefit remains unclear, in part due to the use of non-clinical high doses and reliance on immunodeficient murine models in preclinical studies. Here, we analyzed data from the TriNetX US Collaborative Network to evaluate the association between statin use and survival in ovarian cancer patients, confirming a survival benefit in a large U.S. cohort. We next investigated the protective effects in a syngeneic ascites tumor model of ovarian cancer. Mice treated with clinically relevant doses of lipophilic atorvastatin (ATO) exhibited prolonged survival. Single-cell transcriptomic analyses further revealed enhanced CD8+ T-cell activation programs and pro-inflammatory macrophage remodeling. Flow cytometry identified increased M1-like macrophages and activated CD8+ T-cell populations. Cytokine profiling and transcriptomic analyses indicated that IL-15 signaling was significantly elevated following ATO treatment. Multiplex immunofluorescence analyses demonstrated enhanced tertiary lymphoid structure (TLS)-associated immune organization in metastatic tumor tissues after ATO treatment, with increased T- and B-cell markers. Ex vivo culture of primary T cells with ascites supernatant from ATO-treated mice resulted in enhanced T-cell activation and migratory capacity compared with supernatant from DMSO-treated mice. Collectively, our results suggest that daily statin use may remodel the body environment into a more immune-activated state, leading to a long-term beneficial effect on survival in cancer patients, as observed in large epidemiological studies.

cancer biology↗